Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently showcased promising preclinical data supporting the advancement of two first-in-class, RNA interference (RNAi)-based investigational…
Tris Pharma Reports Positive Phase 3 Results for Cebranopadol in Acute Pain Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company dedicated to developing innovative pain management therapies, has announced positive…
Frazier Life Sciences Names Gerald Nepom as Senior Advisor Frazier Life Sciences (FLS), a premier investment firm dedicated to advancing groundbreaking therapeutics, has appointed Gerald (Jerry) Nepom, M.D., Ph.D., as…
bioAffinity Cuts $4M in Costs to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing noninvasive diagnostic solutions for early-stage lung cancer and…
Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative small-molecule therapies for immunological, inflammatory, and neurological disorders,…
NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis NeuPath Health Inc. (TSXV: NPTH) (“NeuPath” or the “Company”), a leading provider of chronic pain treatment through its extensive network of clinics, has…
Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly growing biopharmaceutical company dedicated to improving patient lives by developing…
Orbital Therapeutics Strengthens Leadership with the Appointment of Biopharma Veteran Geno Germano to Its Board of Directors Orbital Therapeutics, a pioneering biotechnology company focused on advancing RNA-based medicines to address…
Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy Italfarmaco S.p.A., a global pharmaceutical company dedicated to developing innovative treatments for rare diseases, has provided a comprehensive update on the regulatory…
Leading Cancer Center Adopts Abridge AI for Oncology Documentation Abridge, a leader in AI-driven clinical documentation solutions, has announced an extensive rollout of its AI platform at Memorial Sloan Kettering…
Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development…